The study compared the fasting plasma glucose (FPG) response in individuals with HNF1A-diabetes (N = 18) and type 2 diabetes (N = 18) to therapy with SU (gliclazide) or metformin for 6 weeks. Here, HNF1A is linked to type 2 diabetes mellitus.